SG11202012447YA - Rapamycin analogs and uses thereof - Google Patents
Rapamycin analogs and uses thereofInfo
- Publication number
- SG11202012447YA SG11202012447YA SG11202012447YA SG11202012447YA SG11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA
- Authority
- SG
- Singapore
- Prior art keywords
- rapamycin analogs
- rapamycin
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862685666P | 2018-06-15 | 2018-06-15 | |
PCT/US2019/037507 WO2019241789A1 (en) | 2018-06-15 | 2019-06-17 | Rapamycin analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012447YA true SG11202012447YA (en) | 2021-01-28 |
Family
ID=68842366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012447YA SG11202012447YA (en) | 2018-06-15 | 2019-06-17 | Rapamycin analogs and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (2) | US10980784B2 (ko) |
EP (2) | EP3813946B1 (ko) |
JP (2) | JP7382353B2 (ko) |
KR (1) | KR20210021534A (ko) |
CN (2) | CN112423843B (ko) |
AU (1) | AU2019286524A1 (ko) |
BR (1) | BR112020025283A2 (ko) |
CA (1) | CA3103282A1 (ko) |
CO (1) | CO2020015747A2 (ko) |
EA (1) | EA202092692A1 (ko) |
IL (1) | IL279329A (ko) |
MX (1) | MX2020013630A (ko) |
SG (1) | SG11202012447YA (ko) |
WO (1) | WO2019241789A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3813946B1 (en) | 2018-06-15 | 2024-05-22 | Janssen Pharmaceutica NV | Rapamycin analogs and uses thereof |
BR112021014479A2 (pt) | 2019-01-22 | 2021-10-13 | Aeovian Pharmaceuticals, Inc. | Moduladores de mtorc e seus usos |
BR112022010754A2 (pt) | 2019-12-05 | 2022-08-23 | Anakuria Therapeutics Inc | Análogos de rapamicina e usos dos mesmos |
CN115776907A (zh) | 2020-03-27 | 2023-03-10 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
WO2022020522A2 (en) * | 2020-07-21 | 2022-01-27 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
KR20230136625A (ko) * | 2021-01-22 | 2023-09-26 | 얀센 파마슈티카 엔브이 | 라파마이신 유사체 및 이의 용도 |
CN115097046B (zh) * | 2022-07-07 | 2023-09-26 | 国药集团川抗制药有限公司 | 一种分离雷帕霉素及其杂质的方法 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
AU6711994A (en) | 1993-04-23 | 1994-11-21 | American Home Products Corporation | Rapamycin conjugates and antibodies |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
SG64372A1 (en) * | 1993-12-17 | 1999-04-27 | Novartis Ag | Rapamycin derivatives |
US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
JP3934705B2 (ja) | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
HU228234B1 (en) | 1995-06-09 | 2013-02-28 | Novartis Ag | Rapamycin derivatives, pharmaceutical compositions containing them and their use |
CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
JP2001500126A (ja) | 1996-09-09 | 2001-01-09 | アメリカン・ホーム・プロダクツ・コーポレイション | アルキル化ラパマイシン誘導体 |
US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
EP1212331B1 (en) | 1999-08-24 | 2004-04-21 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
MXPA02005675A (es) | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | Compuestos de pirrolo(2,3-d)pirimidina. |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
CN1826331A (zh) | 2003-04-03 | 2006-08-30 | 塞马福尔药业公司 | Pi-3激酶抑制剂前药 |
CA2527583C (en) | 2003-05-30 | 2013-12-17 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
EP1646634B1 (en) | 2003-07-08 | 2008-11-12 | Novartis AG | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
RS55551B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
US20060189551A1 (en) | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
ATE451381T1 (de) | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
MX2007014049A (es) | 2005-05-12 | 2008-02-11 | Abbott Lab | Activadores de apoptosis. |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
WO2007044813A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
HUE028987T2 (en) | 2005-11-01 | 2017-01-30 | Targegen Inc | BI-aryl-meta-pyrimidine inhibitors of kinases |
ES2436877T3 (es) | 2005-11-17 | 2014-01-07 | OSI Pharmaceuticals, LLC | Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados |
ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US20070203168A1 (en) | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
AR060391A1 (es) | 2006-04-11 | 2008-06-11 | Smithkline Beecham Corp | Compuestos de quinolin tiazolidinadiona, sustituidos con heterociclos, composiciones farmaceuticas que los contienen y usos para preparar medicamentos que inhiben la actividad de pi3 quinasas. |
ATE471940T1 (de) | 2006-04-26 | 2010-07-15 | Hoffmann La Roche | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor |
WO2008014449A2 (en) | 2006-07-28 | 2008-01-31 | Caracal, Inc. | Seed holder for crystal growth reactors |
MX2009002927A (es) | 2006-09-15 | 2009-03-31 | Pfizer Prod Inc | Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3. |
LT2530083T (lt) | 2006-09-22 | 2016-09-26 | Pharmacyclics Llc | Brutono tirozinkinazės inhibitoriai |
JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
CN101861313B (zh) | 2007-03-12 | 2014-06-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
KR20120108042A (ko) | 2008-03-11 | 2012-10-04 | 인사이트 코포레이션 | Jak 억제제로서의 아제티딘 및 시클로부탄 유도체 |
US20090253733A1 (en) | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
ME01111B (me) | 2008-05-23 | 2013-03-20 | Wyeth Llc | Triazinska jedinjenja kao inhibitori p13 kinaze i mtor |
CA2728183C (en) | 2008-06-20 | 2016-10-25 | Astrazeneca Ab | Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pryimidines |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
NZ595372A (en) | 2009-03-27 | 2013-11-29 | Vetdc Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
RU2506264C2 (ru) | 2009-04-03 | 2014-02-10 | Вэрастэм, Инк. | Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ) |
WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
RU2589696C2 (ru) | 2010-04-13 | 2016-07-10 | Новартис Аг | КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА |
AR084706A1 (es) | 2010-07-16 | 2013-06-05 | Piramal Life Sciences Ltd | Derivados sustituidos de imidazoquinolinas como inhibidores de quinasa y proceso para su preparacion |
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
EP2589383A1 (en) * | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
US8808256B2 (en) | 2012-01-16 | 2014-08-19 | Johnson & Johnson Vision Care, Inc. | Eye drug delivery system |
US9072678B2 (en) | 2013-03-14 | 2015-07-07 | Pathak Holdings Llc | Methods for local drug delivery by microinjection |
US9663508B2 (en) | 2013-10-01 | 2017-05-30 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
PL3102576T3 (pl) | 2014-02-03 | 2019-12-31 | Vitae Pharmaceuticals, Llc | Dihydropirolopirydynowe inhibitory ror-gamma |
CN107073066B (zh) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
US20160279108A1 (en) | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
CN110770243A (zh) * | 2017-05-02 | 2020-02-07 | 锐新医药公司 | 作为mtor抑制剂的雷帕霉素类似物 |
UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
EP3813946B1 (en) | 2018-06-15 | 2024-05-22 | Janssen Pharmaceutica NV | Rapamycin analogs and uses thereof |
WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
CA3122922A1 (en) | 2018-12-18 | 2020-06-25 | Novartis Ag | Rapamycin derivatives |
BR112021014479A2 (pt) | 2019-01-22 | 2021-10-13 | Aeovian Pharmaceuticals, Inc. | Moduladores de mtorc e seus usos |
MX2021011376A (es) | 2019-03-26 | 2021-10-13 | Novartis Ag | Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. |
CN115776907A (zh) | 2020-03-27 | 2023-03-10 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
WO2022020522A2 (en) | 2020-07-21 | 2022-01-27 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
-
2019
- 2019-06-17 EP EP19819402.9A patent/EP3813946B1/en active Active
- 2019-06-17 AU AU2019286524A patent/AU2019286524A1/en active Pending
- 2019-06-17 SG SG11202012447YA patent/SG11202012447YA/en unknown
- 2019-06-17 CN CN201980047384.3A patent/CN112423843B/zh active Active
- 2019-06-17 EP EP23209520.8A patent/EP4302827A3/en active Pending
- 2019-06-17 KR KR1020217001301A patent/KR20210021534A/ko unknown
- 2019-06-17 BR BR112020025283-2A patent/BR112020025283A2/pt unknown
- 2019-06-17 CA CA3103282A patent/CA3103282A1/en active Pending
- 2019-06-17 JP JP2020569883A patent/JP7382353B2/ja active Active
- 2019-06-17 WO PCT/US2019/037507 patent/WO2019241789A1/en active Application Filing
- 2019-06-17 EA EA202092692A patent/EA202092692A1/ru unknown
- 2019-06-17 MX MX2020013630A patent/MX2020013630A/es unknown
- 2019-06-17 US US16/443,298 patent/US10980784B2/en active Active
- 2019-06-17 CN CN202311390677.6A patent/CN117843659A/zh active Pending
-
2020
- 2020-11-25 US US17/104,771 patent/US11944605B2/en active Active
- 2020-12-09 IL IL279329A patent/IL279329A/en unknown
- 2020-12-15 CO CONC2020/0015747A patent/CO2020015747A2/es unknown
-
2023
- 2023-11-06 JP JP2023189414A patent/JP2024012524A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112423843B (zh) | 2023-11-28 |
CN117843659A (zh) | 2024-04-09 |
US20190388401A1 (en) | 2019-12-26 |
EA202092692A1 (ru) | 2021-04-21 |
KR20210021534A (ko) | 2021-02-26 |
EP3813946B1 (en) | 2024-05-22 |
EP3813946A4 (en) | 2022-06-01 |
EP3813946A1 (en) | 2021-05-05 |
CN112423843A (zh) | 2021-02-26 |
US20210220339A1 (en) | 2021-07-22 |
MX2020013630A (es) | 2021-04-28 |
IL279329A (en) | 2021-01-31 |
JP2021528396A (ja) | 2021-10-21 |
WO2019241789A1 (en) | 2019-12-19 |
JP7382353B2 (ja) | 2023-11-16 |
CO2020015747A2 (es) | 2020-12-21 |
AU2019286524A1 (en) | 2021-01-07 |
BR112020025283A2 (pt) | 2021-03-09 |
CA3103282A1 (en) | 2019-12-19 |
US10980784B2 (en) | 2021-04-20 |
EP4302827A2 (en) | 2024-01-10 |
US11944605B2 (en) | 2024-04-02 |
EP4302827A3 (en) | 2024-03-13 |
JP2024012524A (ja) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275468A (en) | Incretin analogs and their use | |
IL275469A (en) | Incretin analogs and their use | |
IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
IL279329A (en) | Rapamycin analogs and their uses | |
FI3687999T3 (fi) | Rapamysiinijohdannaisia | |
GB202005105D0 (en) | n | |
GB201803568D0 (en) | Novel compounds and uses | |
GB201818605D0 (en) | Nivel use | |
GB201820521D0 (en) | n | |
IL277502A (en) | Compounds and uses for them | |
IL279483A (en) | Cyanotriazole compounds and their uses | |
GB201818712D0 (en) | Accelerometer | |
GB201918689D0 (en) | n | |
GB201701986D0 (en) | n | |
GB201701848D0 (en) | Reciever | |
ZA201904806B (en) | Glove structure | |
GB201813378D0 (en) | n | |
GB2570714B (en) | Accelerometers | |
GB201803571D0 (en) | Component | |
GB201801102D0 (en) | New compounds and uses | |
GB202002530D0 (en) | N | |
EP3897667A4 (en) | SALICYL ADENOSIN MONOSULFAMATE ANALOGUES AND THEIR USES | |
GB201813568D0 (en) | Component | |
GB201806349D0 (en) | New compounds and uses | |
GB201707846D0 (en) | Use |